These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2732137)

  • 1. Activity of FCE 22101 and other beta-lactam antibiotics against experimental genital infections in the rat and mouse.
    Castellani P; Meinardi G; Della Bruna C
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():157-63. PubMed ID: 2732137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of FCE 22891 compared with cefuroxime axetil and cefixime in pulmonary and subcutaneous infections in mice.
    Rossi R; Castellani P; Younes G; Della Bruna C
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():149-55. PubMed ID: 2732136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of FCE 22101 and synergy studies with other antimicrobial agents.
    Chin NX; Neu HC
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():95-101. PubMed ID: 2786520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of a new penem FCE 22101.
    Hoban DJ
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():53-7. PubMed ID: 2786518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic therapy of obstetric and gynecologic infections.
    Gorbach SL
    Surg Clin North Am; 1975 Dec; 55(6):1373-8. PubMed ID: 1198295
    [No Abstract]   [Full Text] [Related]  

  • 6. FCE 22101 and FCE 22891: in-vitro antibacterial activity at concentrations simulating human plasma levels following intravenous, intramuscular and oral administration.
    Della Bruna C; Jabes D; Rossi R; Younes G; Castellani P
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():119-28. PubMed ID: 2659570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity of FCE 22101 and other beta-lactam antibiotics against Enterobacteriaceae resistant to third generation cephalosporins.
    Jarlier V; Nicolas MH; Philippon A; Giroir AM; Grosset J
    J Antimicrob Chemother; 1989 Aug; 24(2):165-72. PubMed ID: 2676939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of FCE 22101 against respiratory tract pathogens with reference to production of beta-lactamases.
    Dornbusch K; Kronvall G; Göransson E; Mörtsell E
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():31-41. PubMed ID: 2786517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in-vitro activity of the penem FCE 22101 against recent European blood culture isolates.
    Dornbusch K; Kronvall G; Göransson E; Mörtsell E
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():43-52. PubMed ID: 2732143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of the penem, FCE 22101, and tentative interpretive criteria for disc susceptibility tests.
    Barry AL; Jones RN; Thornsberry C
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():17-30. PubMed ID: 2732139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics.
    Neu HC; Chin NX; Labthavikul P
    J Antimicrob Chemother; 1985 Sep; 16(3):305-13. PubMed ID: 2997100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative inhibitory and bactericidal activities of FCE 22101 against gram-positive cocci and anaerobes in vitro.
    Maskell JP; Tang T; Asad S; Williams JD
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():65-74. PubMed ID: 2732145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tinidazole in the treatment of surgical and gynaecological infections.
    Giamarellou H; Gazis J; Vlachos G; Michalopoulos A; Aravantinos P; Daikos GK
    J Antimicrob Chemother; 1982 Aug; 10 Suppl A():129-36. PubMed ID: 7118769
    [No Abstract]   [Full Text] [Related]  

  • 14. Toxicological profile of FCE 22101 and its orally available ester FCE 22891.
    Brughera M; Scampini G; Ferrari ML; Nava A; Mazué G
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():129-35. PubMed ID: 2732134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection.
    Powell LL; Wilson SE
    Surg Infect (Larchmt); 2000; 1(1):57-63. PubMed ID: 12594910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational antibiotic therapy and the position of ampicillin/sulbactam.
    Lode HM
    Int J Antimicrob Agents; 2008 Jul; 32(1):10-28. PubMed ID: 18539004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity of FCE 22101 against relatively resistant blood culture isolates.
    Qadri SM; Ueno Y; Ellis ME
    Chemotherapy; 1991; 37(1):15-22. PubMed ID: 2013238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of FCE 22101 compared with imipenem and with gentamicin plus metronidazole in the treatment of experimental intra-abdominal infections in rats.
    Nord CE; Lahnborg G
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():137-41. PubMed ID: 2732135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of chemoprophylaxis against Enterococcus species in elective cholecystectomy: a randomized study of cefuroxime vs ampicillin-sulbactam.
    Dervisoglou A; Tsiodras S; Kanellakopoulou K; Pinis S; Galanakis N; Pierakakis S; Giannakakis P; Liveranou S; Ntasiou P; Karampali E; Iordanou C; Giamarellou H
    Arch Surg; 2006 Dec; 141(12):1162-7. PubMed ID: 17178957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of beta-lactamases in Africa: correlation with resistance to beta-lactam antibiotics.
    Dowse LJ; Prigent BM
    Clin Ther; 1991; 13(2):243-53. PubMed ID: 1863940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.